Kiriakidou M, Ching C. Systemic lupus erythematosus. J Ann Intern Med. 2020;172:ITC81–96.
Tsokos GC. Systemic lupus erythematosus. N Engl J Med. 2011;365:2110–21.
Article CAS PubMed Google Scholar
Barber MRW, Drenkard C, Falasinnu T, Hoi A, Mak A, Kow NY, et al. Global epidemiology of systemic lupus erythematosus. Nat Rev Rheumatol. 2021;17:515–32.
Article PubMed PubMed Central Google Scholar
Greenwood J, Steinman L, Zamvil SS. Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. Nat Rev Immunol. 2006;6:358–70.
Article CAS PubMed Google Scholar
Cholesterol Treatment Trialists’ Collaboration, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet (London, England). 2010;376:1670–81.
Mollazadeh H, Tavana E, Fanni G, Bo S, Banach M, Pirro M, et al. Effects of statins on mitochondrial pathways. J Cachexia Sarcopenia Muscle. 2021;12:237–51.
Article PubMed PubMed Central Google Scholar
Greenwood J, Steinman L, Zamvil SS. Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. Nat Rev Immunol. 2006;6:358–70.
Article CAS PubMed Google Scholar
Fasano S, Margiotta DP, Navarini L, Pierro L, Pantano I, Riccardi A, et al. Primary prevention of cardiovascular disease in patients with systemic lupus erythematosus: case series and literature review. Lupus. 2017;26:1463–72.
Article CAS PubMed Google Scholar
Li GM, Zhao J, Li B, Zhang XF, Ma JX, Ma XL, et al. The anti-inflammatory effects of statins on patients with rheumatoid arthritis: a systemic review and meta-analysis of 15 randomized controlled trials. Autoimmun Rev. 2018;17:215–25.
Article CAS PubMed Google Scholar
Youssef S, Stüve O, Patarroyo JC, Ruiz PJ, Radosevich JL, Hur EM, et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature. 2002;420:78–84.
Article CAS PubMed Google Scholar
Zeiser R. Immune modulatory effects of statins. Immunology. 2018;154:69–75.
Article CAS PubMed PubMed Central Google Scholar
Watanabe T, Oku K, Amengual O, Hisada R, Ohmura K, Nakagawa I, et al. Effects of statins on thrombosis development in patients with systemic lupus erythematosus and antiphospholipid antibodies. Lupus. 2018;27:225–34.
Article CAS PubMed Google Scholar
Artola RT, Mihos CG, Santana O. Effects of statin therapy in patients with systemic lupus erythematosus. South Med J. 2016;109:705–11.
Kwak B, Mulhaupt F, Myit S, Mach F. Statins as a newly recognized type of immunomodulator. Nat Med. 2000;6:1399–402.
Article CAS PubMed Google Scholar
Lawman S, Mauri C, Jury E, Cook H, Ehrenstein M. Atorvastatin inhibits autoreactive B cell activation and delays lupus development in New Zealand black/white F1 mice. J Immunol. 2004;173:7641–6.
Article CAS PubMed Google Scholar
Graham KL, Lee LY, Higgins JP, Steinman L, Utz PJ, Ho PP. Failure of oral atorvastatin to modulate a murine model of systemic lupus erythematosus. Arthritis Rheum. 2008;58:2098–104.
Article CAS PubMed PubMed Central Google Scholar
Theofilopoulos AN, Dixon FJ. Etiopathogenesis of murine SLE. Immunol Rev. 1981;55:179–216.
Article CAS PubMed Google Scholar
Moore E, Putterman C. Are lupus animal models useful for understanding and developing new therapies for human SLE? J Autoimmun. 2020;112:102490.
Article CAS PubMed PubMed Central Google Scholar
Laing ST. High-intensity statins: guideline expectations and clinical application. JAMA. 2017;317:2543–4.
Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139:e1082–143.
Tao X, Fan F, Hoffmann V, Longo NS, Lipsky PE. Therapeutic impact of the ethyl acetate extract of Tripterygium wilfordii Hook F on nephritis in NZB/W F1 mice. Arthritis Res Ther. 2006;8:R24.
Article PubMed PubMed Central Google Scholar
Pisetsky DS. Evolving story of autoantibodies in systemic lupus erythematosus. J Autoimmun. 2020;110:102356.
Article CAS PubMed Google Scholar
Wang X, Xia Y. Anti-double stranded DNA antibodies: origin, pathogenicity, and targeted therapies. Front Immunol. 2019;10:1667.
Article CAS PubMed PubMed Central Google Scholar
Kim AHJ, Strand V, Sen DP, Fu Q, Mathis NL, Schmidt MJ, et al. Association of blood concentrations of complement split product iC3b and serum C3 with systemic lupus erythematosus disease activity. Arthritis Rheumatol (Hoboken, NJ). 2019;71:420–30.
Lawman S, Mauri C, Jury EC, Cook HT, Ehrenstein MR. Atorvastatin inhibits autoreactive B cell activation and delays lupus development in New Zealand black/white F1 mice. J Immunol (Baltimore, Md: 1950). 2004;173:7641–6.
Sahebkar A, Rathouska J, Derosa G, Maffioli P, Nachtigal P. Statin impact on disease activity and C-reactive protein concentrations in systemic lupus erythematosus patients: a systematic review and meta-analysis of controlled trials. Autoimmun Rev. 2016;15:344–53.
Article CAS PubMed Google Scholar
Ho A, Barr SG, Magder LS, Petri M. A decrease in complement is associated with increased renal and hematologic activity in patients with systemic lupus erythematosus. Arthritis Rheum. 2001;44:2350–7.
Article CAS PubMed Google Scholar
Thurman JM. Complement in kidney disease: core curriculum 2015. Am J Kidney Dis. 2015;65:156–68.
Lee H-Y, Ahn J, Park J, Kyung Kang C, Won S-H, Wook Kim D, et al. Beneficial effect of statins in COVID-19-related outcomes-brief report: a national population-based cohort study. Arterioscler Thromb Vasc Biol. 2021;41:e175–82.
Article CAS PubMed PubMed Central Google Scholar
Dotan A, Muller S, Kanduc D, David P, Halpert G, Shoenfeld Y. The SARS-CoV-2 as an instrumental trigger of autoimmunity. Autoimmun Rev. 2021;20:102792.
Article CAS PubMed PubMed Central Google Scholar
Bianchi S, Bigazzi R, Caiazza A, Campese VM. A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Am J Kidney Dis. 2003;41:565–70.
Article CAS PubMed Google Scholar
McCarey DW, McInnes IB, Madhok R, Hampson R, Scherbakov O, Ford I, et al. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet (London, England). 2004;363:2015–21.
Article CAS PubMed Google Scholar
Abud-Mendoza C, de la Fuente H, Cuevas-Orta E, Baranda L, Cruz-Rizo J, González-Amaro R. Therapy with statins in patients with refractory rheumatic diseases: a preliminary study. Lupus. 2003;12:607–11.
留言 (0)